http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003044876-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-96433 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2337-12 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-37 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-37 |
| filingDate | 2002-04-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_45a53cd982044e68687f452fcfbc7132 |
| publicationDate | 2003-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2003044876-A1 |
| titleOfInvention | Test system for the determination of in-vivo active hemostasis proteases or of trypsin or subtilisin in biological fluids and/or the usage thereof to determine the in-vivo activation of hemostasis or to diagnose a pancreatitis |
| abstract | Test system for the determination of in-vivo active hemostasis proteases or of trypsin or subtilisin in biological fluids and the usage thereof to determine the in-vivo activation of hemostasis or to diagnose a pancreatitis. n The present invention describes a global assay of in vivo coagulation activation (GACA), i.e. the global determination of the in vivo activation of hemostasis, particularly of the in vivo activation of coagulation, of biological fluids, particularly of blood and/or plasma and the determination of in-vivo active trypsin and/or subtilisin. The sample to be tested, preferably a sample anticoagulated with EDTA and/or arginine (or guanidine), is incubated according to the invention with a chromogenic or fluorogenic substrate, particularly for Thrombin and/or Factor Xa and/or other enzymes of hemostasis in presence and/or absence of a contact activator and preferably in presence of EDTA. By detection of the absorbance, fluorescence and/or extinction of samples before and after the incubation the in-vivo activation of hemostasis of the biological fluid or the severity of a pancreatitis is determined. The resulting activity is compared with a known standard and indicated in percent of norm in relation to a 100% normal standard human plasma. The normal range is 100%±50% (mean±2 standard deviations). The GACA-activity of normal human plasma corresponds to a pure standard of 6 mlU/ml Thrombin. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2019004031-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11480559-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006019234-A1 |
| priorityDate | 2001-04-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 130.